Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease

OBJECTIVE: Preclinical evidence with nilotinib, a US Food and Drug Administration (FDA)‐approved drug for leukemia, indicates improvement in Alzheimer's disease phenotypes. We investigated whether nilotinib is safe, and detectable in cerebrospinal fluid, and alters biomarkers and clinical decli...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Raymond S., Hebron, Michaeline L., Lawler, Abigail, Mundel, Elizabeth E., Yusuf, Nadia, Starr, J. Nathan, Anjum, Muhammad, Pagan, Fernando, Torres‐Yaghi, Yasar, Shi, Wangke, Mulki, Sanjana, Ferrante, Dalila, Matar, Sara, Liu, Xiaoguang, Esposito, Giuseppe, Berkowitz, Frank, Jiang, Xiong, Ahn, Jaeil, Moussa, Charbel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383852/
https://www.ncbi.nlm.nih.gov/pubmed/32468646
http://dx.doi.org/10.1002/ana.25775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383852/
https://www.ncbi.nlm.nih.gov/pubmed/32468646
http://dx.doi.org/10.1002/ana.25775

Ejemplares similares